Abstract
A reversal of key HIV protease mutations against tipranavir has been observed in a patient undergoing a late salvage antiretroviral therapy. Our patient initially introduced tipranavir/ritonavir in absence of an optimized background and novel drug classes, and nevertheless he experienced a virological-immunological benefit. Our report is a contribution to the present debate around the role of each single HIV protease mutation, and the validation of mutational “scores” (like the so-called tipranavir weighted score), to be applied to last-generation protease inhibitor compounds initially targeted on patients with limited, residual therapeutic options.
Keywords: Antiretroviral therapy, tipranavir, genotypic mutations, reversal of key mutations, tipranavir mutation score, salvage antiretroviral therapy
Current HIV Research
Title: Reversal of Major Genotypic Tipranavir Mutations Under Long-Term Treatment with Tipranavir/Ritonavir Itself with Very Limited Optimized Background, During Deep Salvage Antiretroviral Therapy
Volume: 7 Issue: 3
Author(s): Sergio Sabbatani, Roberto Manfredi, Ciro Fulgaro and Isabella Bon
Affiliation:
Keywords: Antiretroviral therapy, tipranavir, genotypic mutations, reversal of key mutations, tipranavir mutation score, salvage antiretroviral therapy
Abstract: A reversal of key HIV protease mutations against tipranavir has been observed in a patient undergoing a late salvage antiretroviral therapy. Our patient initially introduced tipranavir/ritonavir in absence of an optimized background and novel drug classes, and nevertheless he experienced a virological-immunological benefit. Our report is a contribution to the present debate around the role of each single HIV protease mutation, and the validation of mutational “scores” (like the so-called tipranavir weighted score), to be applied to last-generation protease inhibitor compounds initially targeted on patients with limited, residual therapeutic options.
Export Options
About this article
Cite this article as:
Sabbatani Sergio, Manfredi Roberto, Fulgaro Ciro and Bon Isabella, Reversal of Major Genotypic Tipranavir Mutations Under Long-Term Treatment with Tipranavir/Ritonavir Itself with Very Limited Optimized Background, During Deep Salvage Antiretroviral Therapy, Current HIV Research 2009; 7 (3) . https://dx.doi.org/10.2174/157016209788347994
DOI https://dx.doi.org/10.2174/157016209788347994 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers